ImmuCell (ICCC) plans a controlled launch of Re-Tain, a treatment for dairy cows with subclinical mastitis, which affects milk production.
"This investigational strategy allows us to collect product performance data" while the full non-administrative new animal drug application submission is in the final stages of review, the company said Wednesday in a statement.
Clearing inspectional observations at the contract manufacturer's facilities "is still the critical path constraint" for approval, the company said.
The test marketing isn't expected to generate significant revenue or profit, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.